X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (36676) 36676
Newsletter (379) 379
Magazine Article (43) 43
Newspaper Article (26) 26
Book Chapter (24) 24
Dissertation (15) 15
Publication (7) 7
Conference Proceeding (5) 5
Government Document (5) 5
Report (4) 4
Reference (2) 2
Journal / eJournal (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28878) 28878
female (22466) 22466
cyclophosphamide - administration & dosage (20676) 20676
male (16437) 16437
middle aged (15272) 15272
antineoplastic combined chemotherapy protocols - therapeutic use (14380) 14380
adult (14190) 14190
cyclophosphamide (13680) 13680
oncology (11786) 11786
aged (10620) 10620
doxorubicin - administration & dosage (8818) 8818
chemotherapy (7665) 7665
vincristine - administration & dosage (7641) 7641
treatment outcome (6644) 6644
animals (6435) 6435
hematology (5450) 5450
cyclophosphamide - therapeutic use (5447) 5447
antineoplastic combined chemotherapy protocols - administration & dosage (5285) 5285
cancer (4995) 4995
prednisone - administration & dosage (4959) 4959
antineoplastic combined chemotherapy protocols - adverse effects (4884) 4884
adolescent (4781) 4781
combined modality therapy (4645) 4645
breast neoplasms - drug therapy (4599) 4599
cyclophosphamide - adverse effects (4402) 4402
mice (4106) 4106
prognosis (3993) 3993
therapy (3987) 3987
methotrexate - administration & dosage (3776) 3776
drug administration schedule (3640) 3640
drug therapy, combination (3279) 3279
retrospective studies (3099) 3099
child (3061) 3061
fluorouracil - administration & dosage (3048) 3048
etoposide - administration & dosage (3028) 3028
follow-up studies (2995) 2995
disease-free survival (2968) 2968
cisplatin - administration & dosage (2919) 2919
time factors (2885) 2885
rituximab (2855) 2855
transplantation (2775) 2775
neoplasm staging (2734) 2734
remission induction (2729) 2729
care and treatment (2726) 2726
survival rate (2593) 2593
breast cancer (2533) 2533
survival analysis (2411) 2411
dose-response relationship, drug (2341) 2341
aged, 80 and over (2326) 2326
immunology (2303) 2303
cyclophosphamide - pharmacology (2230) 2230
breast neoplasms - pathology (2222) 2222
doxorubicin (2170) 2170
antineoplastic agents - administration & dosage (2107) 2107
child, preschool (2088) 2088
medicine & public health (2081) 2081
survival (2054) 2054
research (2005) 2005
prospective studies (1849) 1849
chemotherapy, adjuvant (1828) 1828
pharmacology & pharmacy (1812) 1812
rats (1719) 1719
lymphoma, non-hodgkin - drug therapy (1711) 1711
immunosuppressive agents - therapeutic use (1693) 1693
risk factors (1655) 1655
prednisolone - administration & dosage (1648) 1648
antineoplastic agents - therapeutic use (1625) 1625
immunosuppressive agents - administration & dosage (1621) 1621
analysis (1613) 1613
trial (1594) 1594
doxorubicin - adverse effects (1581) 1581
young adult (1574) 1574
recurrence (1568) 1568
health aspects (1557) 1557
ovarian neoplasms - drug therapy (1499) 1499
bleomycin - administration & dosage (1498) 1498
clinical trials as topic (1483) 1483
lung neoplasms - drug therapy (1478) 1478
drug therapy (1401) 1401
lymphoma, large b-cell, diffuse - drug therapy (1394) 1394
toxicity (1383) 1383
cisplatin (1365) 1365
hematopoietic stem cell transplantation (1363) 1363
epirubicin - administration & dosage (1352) 1352
dosage and administration (1349) 1349
lymphomas (1305) 1305
cytarabine - administration & dosage (1285) 1285
vincristine - therapeutic use (1267) 1267
doxorubicin - therapeutic use (1258) 1258
medicine, general & internal (1255) 1255
prednisone - therapeutic use (1242) 1242
non-hodgkins-lymphoma (1223) 1223
carcinoma (1222) 1222
paclitaxel (1218) 1218
methotrexate (1208) 1208
paclitaxel - administration & dosage (1203) 1203
immunotherapy (1199) 1199
infant (1195) 1195
stem cells (1187) 1187
disease (1186) 1186
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33313) 33313
Japanese (1725) 1725
German (713) 713
Russian (625) 625
French (486) 486
Chinese (346) 346
Spanish (279) 279
Polish (231) 231
Italian (147) 147
Hungarian (44) 44
Czech (38) 38
Portuguese (33) 33
Dutch (23) 23
Croatian (17) 17
Hebrew (11) 11
Bulgarian (10) 10
Romanian (10) 10
Norwegian (9) 9
Ukrainian (9) 9
Slovak (8) 8
Danish (7) 7
Korean (7) 7
Serbian (7) 7
Finnish (5) 5
Swedish (5) 5
Turkish (5) 5
Persian (4) 4
Lithuanian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 2016, Volume 34, Issue 17, pp. 2020 - 2027
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 15, pp. 1408 - 1416
A dose-intense infusional chemotherapy program plus rituximab had a high degree of efficacy in patients with primary mediastinal B-cell lymphoma, which is... 
MEDICINE, GENERAL & INTERNAL | AMPLIFICATION | MANAGEMENT | EFFICACY | DOXORUBICIN | SCLEROSIS | CLASSICAL HODGKIN LYMPHOMA | RADIOTHERAPY | EXPRESSION | GERMINAL-CENTER | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cyclophosphamide - adverse effects | Filgrastim | Dose-Response Relationship, Drug | Young Adult | Vincristine - administration & dosage | Adult | Female | Retrospective Studies | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Etoposide - adverse effects | Lymphoma, Large B-Cell, Diffuse - drug therapy | Prednisone - adverse effects | Kaplan-Meier Estimate | Rituximab | Stroke Volume - drug effects | Etoposide - administration & dosage | Recombinant Proteins - administration & dosage | Disease-Free Survival | Vincristine - adverse effects | Aged | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Drugs | Dose-response relationship (Biochemistry) | Usage | Cyclophosphamide | Patient outcomes | Dosage and administration | Lymphomas | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Doxorubicin | Medical research | Nuclear magnetic resonance--NMR | Disease | Review boards | Genes | Etoposide | Prednisone | Radiation therapy | Kinases | Vincristine | Patients | Morbidity | Chemotherapy | Lymphocytes B | Remission | Mutation | Hodgkin's disease | B-cell lymphoma
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | THERAPY | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | LEUKEMIA | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2010, Volume 28, Issue 27, pp. 4199 - 4206
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2015, Volume 126, Issue 6, pp. 721 - 732
Waldenstrom macroglobulinemia (WM) is a B-cell neoplasm manifested by the accumulation of clonal immunoglobulin (Ig)M-secreting lymphoplasmacytic cells. MYD88... 
CONSENSUS PANEL RECOMMENDATIONS | 2ND INTERNATIONAL WORKSHOP | L265P SOMATIC MUTATION | MULTIPLE-MYELOMA | RITUXIMAB THERAPY | IMMUNOGLOBULIN-M | MYD88 L265P | LYMPHOPROLIFERATIVE DISORDERS | LYMPHOPLASMACYTIC CELLS | INHIBITOR EVEROLIMUS | HEMATOLOGY | Cyclophosphamide - administration & dosage | Nitrogen Mustard Compounds - administration & dosage | Waldenstrom Macroglobulinemia - therapy | Humans | Middle Aged | Pyrazines - administration & dosage | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Transplantation, Autologous | Molecular Targeted Therapy | Waldenstrom Macroglobulinemia - pathology | Adult | Receptors, CXCR4 - genetics | B-Lymphocytes - pathology | Boronic Acids - administration & dosage | Everolimus | B-Lymphocytes - metabolism | Waldenstrom Macroglobulinemia - diagnosis | Immunoglobulin M - genetics | Gene Expression | Genetic Predisposition to Disease | Sirolimus - analogs & derivatives | Bortezomib | Pyrimidines - administration & dosage | Myeloid Differentiation Factor 88 - genetics | Antineoplastic Combined Chemotherapy Protocols | Hematopoietic Stem Cell Transplantation | Rituximab | Vidarabine - analogs & derivatives | Cladribine - administration & dosage | Plasmapheresis | Receptors, CXCR4 - metabolism | B-Lymphocytes - drug effects | Sirolimus - administration & dosage | Pyrazoles - administration & dosage | Bendamustine Hydrochloride | Aged | Oligopeptides - administration & dosage | Vidarabine - administration & dosage | Myeloid Differentiation Factor 88 - metabolism | Waldenstrom Macroglobulinemia - genetics
Journal Article
Blood, ISSN 1528-0020, 2013, Volume 122, Issue 7, pp. 1214 - 1221
Detection of MRD by real-time quantitative PCR and flow cytometry is an important predictor of outcome in patients with Ph+ ALL. 
ADULT PATIENTS | HYPER-CVAD | GENE REARRANGEMENTS | STANDARD-RISK | QUANTIFICATION | ACUTE LYMPHOBLASTIC-LEUKEMIA | FLOW-CYTOMETRY | STEM-CELL TRANSPLANTATION | HEMATOLOGY | MINIMAL RESIDUAL DISEASE | CLINICAL-SIGNIFICANCE | Piperazines - administration & dosage | Cyclophosphamide - administration & dosage | Prognosis | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality | Thiazoles - administration & dosage | Neoplasm Recurrence, Local - mortality | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Benzamides - administration & dosage | Flow Cytometry | Neoplasm, Residual - diagnosis | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Neoplasm, Residual - mortality | Philadelphia Chromosome | Real-Time Polymerase Chain Reaction | Doxorubicin - administration & dosage | Dasatinib | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Pyrimidines - administration & dosage | RNA, Messenger - genetics | Survival Rate | Reverse Transcriptase Polymerase Chain Reaction | Imatinib Mesylate | Remission Induction | Cytarabine - administration & dosage | Neoplasm, Residual - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Fusion Proteins, bcr-abl - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Immunoglobulin Heavy Chains - genetics | Lymphoid Neoplasia
Journal Article
British journal of cancer, ISSN 1532-1827, 2014, Volume 111, Issue 6, pp. 1072 - 1079
Background: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is a devastating complication; the optimal prophylactic strategy... 
cytarabine | INTERMEDIATE-GRADE | FOLLOW-UP | diffuse large B-cell lymphoma | methotrexate intrathecal | CHEMOTHERAPY | central nervous system | RELAPSE | central nervous system prophylaxis | ONCOLOGY | STANDARD CHOP | NON-HODGKINS-LYMPHOMA | CNS PROPHYLAXIS | AGGRESSIVE LYMPHOMA | RITUXIMAB ERA | ELDERLY-PATIENTS | Recurrence | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Male | Central Nervous System Neoplasms - secondary | Young Adult | Central Nervous System Neoplasms - prevention & control | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Acute Kidney Injury - chemically induced | Retrospective Studies | Doxorubicin - administration & dosage | Injections, Spinal | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Lymphoma, Large B-Cell, Diffuse - drug therapy | Lymphoma, Large B-Cell, Diffuse - pathology | Risk Assessment | Rituximab | Etoposide - administration & dosage | Survival Rate | Cytarabine - administration & dosage | Disease-Free Survival | Methotrexate - adverse effects | Administration, Intravenous | Ifosfamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Methotrexate - administration & dosage | Aged | intrathecal | methotrexate | Clinical Study
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 9, pp. 869 - 878
Journal Article
11.